Although clinical trials of CAR-T cells targeting promising candidate antigens other than CD19 are underway, the number of ideal tumor-specific targets is limited by the number of tumor-specific “cell-surface” antigens that are targetable with conventional monoclonal antibodies. This evidence concerns the gene CD19 and neoplasm.